›› 2017, Vol. 37 ›› Issue (6): 822-.doi: 10.3969/j.issn.1674-8115.2017.06.019

Previous Articles     Next Articles

Chimeric antigen receptor T-cell immunotherapy and its applications in hematological malignancies immunotherapy

XIA Li, WANG Yue-ying   

  1. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
  • Online:2017-06-28 Published:2017-07-05
  • Supported by:

    National Natural Science Foundation of China, 81570151; Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant Support, 20152507; Shanghai Jiao Tong University SMC-Morningstar Young Scholars Program


 Chimeric antigen receptor T-cell (CAR-T) immunotherapy is a new type of immunotherapy, which has been developed rapidly in recent years. By using gene recombination and transfection techniques, CAR-modified effector T cells that specially recognize tumor-associated antigen was produced, which show better properties of targeting, killing activity and durability than conventional T cells. With the development of translational medicine research, CAR-T technology has experienced four generations of optimization and innovation, and presented a promising clinical efficacy in the treatment of various cancers, especially hematological malignancies. However, there are also potential risks with clinical use of this new technology, such as the off-target effect and cytokine storm. In this review, the progress, side effects, coping strategy, and development prospects of CAR-T in hematological malignancies immunotherapy were discussed.

Key words: chimeric antigen receptor T-cell immunotherapy , hematological malignancies, cellular immunotherapy